Lilly declares first-quarter 2026 dividend
Eli Lilly (NYSE: LLY) declared a first-quarter 2026 dividend of $1.73 per share on outstanding common stock.
Rhea-AI Summary
Eli Lilly (NYSE: LLY) declared a first-quarter 2026 dividend of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 13, 2026.
Positive
- Dividend declared of $1.73 per share for Q1 2026
- Payment date set for March 10, 2026 with record date Feb 13, 2026
Negative
- Cash outflow to shareholders equal to $1.73 per share
Details
News Market Reaction – LLY
In the Dec 8 session, LLY declined 1.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Q1 2026 dividend
- $1.73 per share
- First-quarter 2026 dividend on common stock
- Payable date
- March 10, 2026
- Q1 2026 dividend payment date
- Record date
- February 13, 2026
- Shareholders of record for Q1 2026 dividend
- Prior dividends
- $1.50 per share
- Q2, Q3, and Q4 2025 declared dividends
- Current price
- $1009.38
- Price before dividend news, <b>-9.23%</b> vs 52‑week high
- 52-week range
- $623.78–$1111.99
- LLY trades 61.82% above its 52‑week low
- New facility spend
- $6 billion
- Planned Alabama API manufacturing facility investment
- Risk reduction
- 80%
- Jaypirca reduced risk of progression or death vs BR
Historical Context
-
Announced >$6B Alabama API facility and thousands of new jobs.
-
Completed Adverum tender offer with cash plus CVR structure.
-
Phase 3 Jaypirca data showed 80% lower progression or death risk.
-
Declared first‑quarter 2026 dividend of $1.73 per share.
-
Reappointed Nobel laureate Carolyn Bertozzi to the board.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-declares-first-quarter-2026-dividend-302635673.html
SOURCE Eli Lilly and Company
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.